T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis

Abstract Background Current guidelines consider T-DM1 the standard 2nd line therapy for HER2 positive metastatic breast cancer (MBC) patients following trastuzumab (T) + pertuzumab (P) and taxane 1st line treatment. Despite this, there are no prospective studies supporting this sequence. Methods We...

Full description

Bibliographic Details
Main Authors: Claudia Omarini, Federico Piacentini, Isabella Sperduti, Krisida Cerma, Monica Barbolini, Fabio Canino, Cecilia Nasso, Christel Isca, Federica Caggia, Massimo Dominici, Luca Moscetti
Format: Article
Language:English
Published: BMC 2022-06-01
Series:BMC Cancer
Subjects:
HER2 positive
T-DM1
Pertuzumab
Trastuzumab emtansine
Metastatic breast cancer
Online Access:https://doi.org/10.1186/s12885-022-09556-7

Similar Items

Similar Items